Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. |
| |
Authors: | B Mukherji N G Chakraborty S Yamasaki T Okino H Yamase J R Sporn S K Kurtzman M T Ergin J Ozols J Meehan et al. |
| |
Affiliation: | B Mukherji, N G Chakraborty, S Yamasaki, T Okino, H Yamase, J R Sporn, S K Kurtzman, M T Ergin, J Ozols, J Meehan, et al. |
| |
Abstract: | Human melanoma cells can process the MAGE-1 gene product and present the processed nonapeptide EADPTGHSY on their major histocompatibility complex class I molecules, HLA-A1, as a determinant for cytolytic T lymphocytes (CTLs). Considering that autologous antigen presenting cells (APCs) pulsed with the synthetic nonapeptide might, therefore, be immunogenic, melanoma patients whose tumor cells express the MAGE-1 gene and who are HLA-A1+ were immunized with a vaccine made of cultured autologous APCs pulsed with the synthetic nonapeptide. Analyses of the nature of the in vivo host immune response to the vaccine revealed that the peptide-pulsed APCs are capable of inducing autologous melanoma-reactive and the nonapeptide-specific CTLs in situ at the immunization site and at distant metastatic disease sites. |
| |
Keywords: | |
|
|